Replies to post #16060 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

I'll update MNTA's cash balance when MNTA files its 3Q16 10-Q; the 10-Q conatins figures not shown in the 3Q16 press release, as can be seen in #msg-124348392 (from 2Q16).

[DewDiligence]

M254 is a new codename in MNTA’s pipeline; from today’s PR:

Momenta is also developing a hyper-sialylated IVIg (M254) as a potential high potency version of IVIg.

Unlike M281 and M230, M254 is plasma-derived, not recombinant.

In the pipeline chart in http://www.momentapharma.com/pipeline/pipeline.php , M254 is the bottommost item.

[DewDiligence]

From today's CC: Glatopa has a 40% volume share of the 20mg portion of the market, which itself comprises 22% of the (20mg + 40mg) US Copaxone market. Thus, Glatopa has a 9% volume share of the overall US Copaxone market.